1.88 USD
▼-0.12-6.02%
盘后 1.95 +4.00%
2026-11-20
市值
$241.19K
市盈率
—
EPS
-102.50
股息率
—
52 周区间
1.85 – 357.60
成交量
24.38K
Beta
1.27
目标价
—
52W 低 1.8552W 高 357.60
价格走势
公司简介
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse m...